Pelacarsen Roll-over Extension Program

PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

January 3, 2028

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

Pelacarsen (TQJ230)

pelacarsen 80mg s.c. monthly

Trial Locations (25)

20706

RECRUITING

Capitol Cardiology Associates, Lanham

20744

RECRUITING

Anderson Medical Research, Ft. Washington

22042

RECRUITING

Virginia Heart, Falls Church

22311

RECRUITING

Javara Research, Alexandria

33013

RECRUITING

National Research Institute, Hialeah

33014

RECRUITING

Inpatient Research Clinical LLC, Miami Lakes

33029

RECRUITING

DBC Research USA, Pembroke Pines

33126

RECRUITING

Finlay Medical Research, Miami

33308

RECRUITING

Proactive Clinical Research, Fort Lauderdale

33434

RECRUITING

Excel Medical Clinical Trials LLC, Boca Raton

33449

RECRUITING

Cardiology Partners Clinical Research Institute, Wellington

35215

RECRUITING

Parkway Medical Center, Birmingham

38301

RECRUITING

Apex Cardiology Research Associates of Jackson, Jackson

48202

RECRUITING

Henry Ford Hospital, Detroit

48504

RECRUITING

Aa Mrc Llc, Flint

70433

RECRUITING

Cardiovascular Associates Research, Covington

70791

RECRUITING

Southern Clin Research Clinic, Zachary

76021

RECRUITING

North Hills Medical Research Inc, Bedford

77025

RECRUITING

Angiocardiac Care of Texas PA, Houston

77084

RECRUITING

Biopharma Informatic LLC, Houston

RECRUITING

Biopharma Informatic LLC, Houston

78229

RECRUITING

Clinical Trials of Texas, San Antonio

89119

RECRUITING

AB Clinical Trials, Las Vegas

89121

RECRUITING

Clinical Research of South Nevada, Las Vegas

90211

RECRUITING

National Heart Institute, Beverly Hills

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY